Genetic polymorphisms of CYP2D6 oxidation in patients with systemic lupus erythematosus

被引:8
作者
Skretkowicz, Jadwiga [1 ]
Baranska, Malgorzata [1 ]
Kaczorowska, Anna [2 ]
Rychlik-Sych, Mariola [1 ]
机构
[1] Med Univ Lodz, Dept Pharmacogenet, PL-90151 Lodz, Poland
[2] Med Univ Lodz, Mil Med Fac, Dept Dermatol & Paediat Dermatol, PL-90151 Lodz, Poland
关键词
genetic polymorphism; oxidation; systemic lupus erythematosus; CANCER RISK; CYTOCHROME-P450; PHARMACOGENETICS; ASSOCIATION; DISEASE;
D O I
10.5114/aoms.2011.25563
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Systemic lupus erythematosus (SLE) is a complex, multifactor autoimmune disease. The studies on aetiopathogenesis of autoimmune diseases focus on the impact the genetically conditioned impairment of xenobiotic metabolism may exert. The knowledge of oxidation polymorphism in the course of SLE may be helpful in choosing more efficient and safer therapy. We determined whether there was an association between susceptibility to SLE and particularly to CYP2D6 genotypes. Material and methods: The study was carried out in 60 patients with SLE and 129 healthy volunteers and all the subjects were of Polish origin. The samples were analysed for two major defective alles for CYP2D6 - CYP2D6(star)3 and CYP2D6(star)4 and one wild -type allele CYP2D6(star)1-by the polymerase chain reaction fragment length polymorphism (PCR-RFLP) metod with DNA extracted from peripheral blood. Results: No statistically significant differences in the incidence of CYP2D6 genotypes between the studied groups were found (p = 0.615). Risk (OR) of SLE development was 1.03 for the carriers of CYP2D6(star)3 allele and 1.48 for the subjects with CYP2D6(star)4 allele; but it was not statistically significant. Conclusions: Increased occurrence of mutant alleles of the CYP2D6 gene in SLE patients and the calculated OR values could suggest the effect of these mutations on increased SLE development.
引用
收藏
页码:864 / 869
页数:6
相关论文
共 30 条
[1]   Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics - Useful aid to prescribing? [J].
Dahl, ML .
CLINICAL PHARMACOKINETICS, 2002, 41 (07) :453-470
[2]   Cytochrome P450 and anticancer drugs [J].
Fujita, K .
CURRENT DRUG METABOLISM, 2006, 7 (01) :23-37
[3]  
Fukuda Tsuyoshi, 2005, Drug Metab Pharmacokinet, V20, P345, DOI 10.2133/dmpk.20.345
[4]  
Gotab-Janowska M, 2007, NEUROL NEUROCHIR POL, V41, P113
[5]   Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].
Hochberg, MC .
ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1725-1725
[6]  
Hosseini M, 2009, ARCH MED SCI, V5, P103
[7]   Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity [J].
Ingelman-Sundberg, M .
PHARMACOGENOMICS JOURNAL, 2005, 5 (01) :6-13
[8]   CYP2D6 polymorphism in systemic lupus erythematosus patients [J].
Kortunay, S ;
Bozkurt, A ;
Bathum, L ;
Basci, NE ;
Calgüneri, M ;
Brosen, K ;
Kayaalp, SO .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (01) :21-25
[9]  
Kot M, 2008, PHARMACOL REP, V60, P789
[10]  
Lapinski L, 2007, PHARMACOL REP, V59, P167